• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.SARS-CoV-2 疫苗研究和免疫策略,以改善对 COVID-19 大流行的控制。
Front Med. 2022 Apr;16(2):185-195. doi: 10.1007/s11684-021-0913-y. Epub 2022 Feb 28.
2
The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.迈向 COVID-19 群体免疫的漫长道路:疫苗平台技术和大规模免疫策略。
Front Immunol. 2020 Jul 21;11:1817. doi: 10.3389/fimmu.2020.01817. eCollection 2020.
3
mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.mRNA 疫苗诱导的 T 细胞对 SARS-CoV-2 关切变异株的反应完全相同,但根据先前的感染状态,其持久性和归巢特性存在差异。
Elife. 2021 Oct 12;10:e72619. doi: 10.7554/eLife.72619.
4
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.SARS-CoV-2 变体和 COVID-19 疫苗:当前的挑战与未来策略。
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
5
A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?对 COVID-19 大流行第一年疫苗接种情况的快速范围综述:我们是需要更多疫苗还是更多时间?
Medicine (Baltimore). 2022 Sep 16;101(37):e30609. doi: 10.1097/MD.0000000000030609.
6
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.SARS-CoV-2 变异株特异性复制 RNA 疫苗可预防同源关切变异株挑战后的疾病。
Elife. 2022 Feb 22;11:e75537. doi: 10.7554/eLife.75537.
7
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
8
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.新冠疫情和疫苗更新:挑战与解决方案。
Front Cell Infect Microbiol. 2021 Sep 10;11:690621. doi: 10.3389/fcimb.2021.690621. eCollection 2021.
9
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19(Sars-Cov-2)的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
10
SARS-CoV-2 Variants, Vaccines, and Host Immunity.SARS-CoV-2 变体、疫苗和宿主免疫。
Front Immunol. 2022 Jan 3;12:809244. doi: 10.3389/fimmu.2021.809244. eCollection 2021.

引用本文的文献

1
Factors Associated with IgG/IgM Levels after SARS-CoV-2 Vaccination in Patients with Head and Neck Cancer.头颈部癌患者接种新型冠状病毒疫苗后IgG/IgM水平的相关因素
Trop Med Infect Dis. 2024 Oct 8;9(10):234. doi: 10.3390/tropicalmed9100234.
2
Sequential Immunization with Vaccines Based on SARS-CoV-2 Virus-like Particles Induces Broadly Neutralizing Antibodies.基于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒样颗粒的疫苗序贯免疫诱导广泛中和抗体。
Vaccines (Basel). 2024 Aug 19;12(8):927. doi: 10.3390/vaccines12080927.
3
A network meta-analysis of risk factors of infection among close contacts of COVID-19.新型冠状病毒肺炎密切接触者感染危险因素的网状Meta分析
Heliyon. 2023 Oct 10;9(10):e20861. doi: 10.1016/j.heliyon.2023.e20861. eCollection 2023 Oct.
4
Machine Learning Classification of Time since BNT162b2 COVID-19 Vaccination Based on Array-Measured Antibody Activity.基于阵列测量抗体活性的BNT162b2 COVID-19疫苗接种后时间的机器学习分类
Life (Basel). 2023 May 31;13(6):1304. doi: 10.3390/life13061304.
5
Analysis on the factors associated with COVID-19 infection among Chinese residents after the implementation of to optimize COVID-19 response: a cross-sectional study.实施“新 10 条”后中国居民 COVID-19 感染相关因素分析:一项横断面研究。
Front Public Health. 2023 Jun 8;11:1197889. doi: 10.3389/fpubh.2023.1197889. eCollection 2023.
6
Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures.利用纳米酶防治 COVID-19:在诊断、治疗和预防措施方面的进展。
J Nanobiotechnology. 2023 Jun 21;21(1):200. doi: 10.1186/s12951-023-01945-9.
7
Covid-19 Prevention and Treatment by Targeting Fc-fusion Proteins: An Experience to Fight Emerging Diseases.靶向Fc融合蛋白预防和治疗新冠病毒病:抗击新发疾病的经验
Curr Mol Med. 2024;24(4):428-434. doi: 10.2174/1566524023666230410093243.
8
A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults.一项关于 COVID-19 疫苗在老年人中的有效性和安全性的系统评价和荟萃分析。
Front Immunol. 2023 Mar 3;14:1113156. doi: 10.3389/fimmu.2023.1113156. eCollection 2023.
9
Attitude and level of COVID-19 vaccination and its determinants among patients with chronic disease visiting Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia: A cross-sectional study.在埃塞俄比亚西北部的德布雷塔博尔综合专科医院就诊的慢性病患者中,COVID-19 疫苗接种的态度和水平及其决定因素:一项横断面研究。
PLoS One. 2022 Dec 9;17(12):e0278914. doi: 10.1371/journal.pone.0278914. eCollection 2022.
10
The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China.中国中部地区医护人员和目标人群对 COVID-19 异源加强免疫接种的接受情况:一项横断面研究。
Front Public Health. 2022 Aug 1;10:943876. doi: 10.3389/fpubh.2022.943876. eCollection 2022.

本文引用的文献

1
Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine.第三剂灭活新型冠状病毒疫苗对B细胞和T细胞反应的强劲诱导作用。
Cell Discov. 2022 Feb 1;8(1):10. doi: 10.1038/s41421-022-00373-7.
2
Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine.两剂灭活疫苗后科兴疫苗或ZF2001加强针的体液免疫原性和反应原性
Cell Res. 2022 Jan;32(1):107-109. doi: 10.1038/s41422-021-00596-5. Epub 2021 Dec 3.
3
Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern.两剂灭活疫苗后接种重组蛋白亚单位疫苗加强针可显著增强针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)及其关注变异株的抗受体结合域(RBD)反应和中和效价。
Cell Res. 2022 Jan;32(1):103-106. doi: 10.1038/s41422-021-00590-x. Epub 2021 Nov 23.
4
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.一种灭活的严重急性呼吸综合征冠状病毒 2 型疫苗(BBV152)的有效性、安全性和批间免疫原性:一项随机、双盲、对照、3 期临床试验的中期结果。
Lancet. 2021 Dec 11;398(10317):2173-2184. doi: 10.1016/S0140-6736(21)02000-6. Epub 2021 Nov 11.
5
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.英国未接种和接种疫苗人群中 SARS-CoV-2 德尔塔(B.1.617.2)变异株的社区传播和病毒载量动力学:一项前瞻性、纵向、队列研究。
Lancet Infect Dis. 2022 Feb;22(2):183-195. doi: 10.1016/S1473-3099(21)00648-4. Epub 2021 Oct 29.
6
Waning Immunity after the BNT162b2 Vaccine in Israel.以色列接种 BNT162b2 疫苗后的免疫力下降。
N Engl J Med. 2021 Dec 9;385(24):e85. doi: 10.1056/NEJMoa2114228. Epub 2021 Oct 27.
7
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.德尔塔变异株对英国新冠病毒载量及针对新型严重急性呼吸综合征冠状病毒2感染的疫苗效力的影响。
Nat Med. 2021 Dec;27(12):2127-2135. doi: 10.1038/s41591-021-01548-7. Epub 2021 Oct 14.
8
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.辉瑞-BioNTech 信使核糖核酸 COVID-19 疫苗在美国大型综合卫生系统中的 6 个月有效性:一项回顾性队列研究。
Lancet. 2021 Oct 16;398(10309):1407-1416. doi: 10.1016/S0140-6736(21)02183-8. Epub 2021 Oct 4.
9
A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases - Wuhan, China 2019-2020.在中国武汉2019 - 2020年肺炎病例群中发现的一种新型冠状病毒基因组
China CDC Wkly. 2020 Jan 24;2(4):61-62.
10
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.2021年3月至8月美国Moderna、辉瑞-生物科技公司和杨森(强生)疫苗在预防无免疫功能低下状况成年人新冠病毒肺炎住院方面的比较效果
MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1337-1343. doi: 10.15585/mmwr.mm7038e1.

SARS-CoV-2 疫苗研究和免疫策略,以改善对 COVID-19 大流行的控制。

SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.

机构信息

Chinese Center for Disease Control and Prevention, Beijing, 102206, China.

Changping Laboratory, Beijing, 102206, China.

出版信息

Front Med. 2022 Apr;16(2):185-195. doi: 10.1007/s11684-021-0913-y. Epub 2022 Feb 28.

DOI:10.1007/s11684-021-0913-y
PMID:35226300
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8883005/
Abstract

The record speed at which Chinese scientists identified severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) and shared its genomic sequence with the world, has greatly facilitated the development of coronavirus disease (COVID-19) diagnostics, drugs, and vaccines. It is unprecedented in pandemic control history to develop a dozen successful vaccines in the first year and to immunize over half of the global population in the second year, due to the efforts of the scientific community, biopharmaceutical industry, and regulatory agencies worldwide. The challenges are both great and multidimensional due to the rapid emergence of virus variants and waning of vaccine immunity. Vaccination strategies need to adapt to these challenges to keep population immunity above the herd immunity threshold, by increasing vaccine coverage, especially for older adults and young people, and providing timely booster doses with homologous or heterologous vaccine boosts. Further research should be undertaken to develop more effective vaccines against SARS-CoV-2 variants and to understand the best prime-boost vaccine combinations and immunization strategies to provide sufficient and sustainable immune protection against COVID-19.

摘要

中国科学家以创纪录的速度鉴定出严重急性呼吸综合征冠状病毒 2(SARS-CoV-2),并与世界分享其基因组序列,这极大地促进了冠状病毒病(COVID-19)诊断、药物和疫苗的研发。由于全球科学界、生物制药行业和监管机构的共同努力,在第一年开发出十几种成功的疫苗,并在第二年为全球一半以上的人口接种疫苗,这在大流行控制史上是前所未有的。由于病毒变异的迅速出现和疫苗免疫力的下降,面临的挑战是巨大的和多方面的。接种策略需要适应这些挑战,通过增加疫苗接种覆盖率,特别是为老年人和年轻人接种疫苗,并及时提供同源或异源疫苗加强针,使人群免疫力保持在群体免疫阈值以上。应进一步开展研究,开发针对 SARS-CoV-2 变异株的更有效的疫苗,并了解最佳的初始-加强疫苗组合和免疫策略,以提供针对 COVID-19 的充足和可持续的免疫保护。